About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD0.40
- USD0.40
- USD0.38
- USD2.53
- -20.30%
- 11M
- 2.05k
- 575.43k
- 22M
- 0.24
- -72.80%
Stock News
3 hours ago
GE Vernova Inc. (GEV): It’s Not Too Late To Say I Missed Out On It, Says Jim Cramer
Yahoo
7 hours ago
TQQQ: Material Outperformance Potential (Rating Upgrade)
SeekingAlpha
7 hours ago
TETRA Technologies: A Hold Pending Investor Day And Greater Visibility On Minerals Project
SeekingAlpha
7 hours ago
Back-To-Back Bulls
SeekingAlpha
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
